No Detail Found!

Phosphate Binder's Adherence and Knowledge among Hemodialysis Patients in Karbala Center, Cross-Sectional Study

Author(s)
Reyadh Jassem Al-Amal Collage Specialized for Medical Science, Iraq
Iman Sabeeh Hasan Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
Liqaa M. Al-Sharifi Hematopathologist, Collage of Medicine, University of Babylon,,Iraq
Firas Ghafil Abba Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
Iman O. Al-shammary Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
Abstract
Among patients with end stage renal disease (ESRD), the Non-adherence to phosphate binder medications represents a big contributor for hyperphosphatemia management failure. Hence, it makes the patient prone for high risk of cardiovascular morbidity and all-cause mortality as a consequence of hyperphosphatemia. Thus, we tend in this study to investigate whether there is an association between adherence, knowledge, serum phosphate, and any of patient demographic characteristics affecting phosphate binder adherence. This study is a cross sectional, descriptive, single arm study for the purpose of evaluating the patient adherence and knowledge toward phosphate binder medications in hemodialysis patients with hyperphosphatemia. This study was conducted at the dialysis Centers in Al_Imam Al Hussein Teaching Hospital. All participating patients were asked to answer two questionnaires [Patient Knowledge questionnaire and Morisky Medication Adherence Scale]. 204 patients participate in the study where the percentage of residence from inside of Karbala was 97.5 %. The study shows the major cause of chronic kidney disease in most patient was hypertension with percentage (N=70, 34.3%), followed by diabetes mellitus by 15.7%. About knowledge, 58% answered accurately about phosphate binders' indication. In regard to the question, ''When should you take your phosphate binder?' 37.2% responded true and around 95% give inappropriate answer about the question' 'What should you do if you have forgotten to take your phosphate binder? ''58% of patients didn't know if there's side effect for phosphate binders or not while 21.9% showed Nausea, vomiting, headache and constipation. In this study, about half of the participants show intermediate adherence 52.4% The phosphate level was significantly low in high adherence group. Phosphate binders widely used among hemodialysis patients. The phosphate level was affected by the extent of adherence to the phosphate binders where high control level of phosphate was seen in high adherence population. About patients' knowledge towards phosphate binders, most of them reported the right answer toward indication of phosphate binder, while those dealing with dosing, their knowledge was insufficient.
Publication Details
Page(s) 2494-2506
Published Journal: Pakistan Journal of Life and Social Sciences, Volume: 22, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
CKD Morsky Score ESRD Phosphate Binders Hemodialysis
References
Tentori F,Blayney MJ,Albert JM .2008 .Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 52(3) : 519-530.
Slatopolsky E,Gonzalez E,Martin K. Pathogenesis .2003 .and treatment of renal osteodystrophy. Blood Purif, 21(4-5) : 318-326.
Malberti F. Hyperphosphataemia .2013 .: treatment options. Drugs, 73(7) : 673-688.
Ketteler M,Biggar PH .2013 .Use of phosphate binders in chronic kidney disease. CurrOpinNephrolHypertens, 22(4) : 413-420.
Lopes AA,Tong L,Thumma J .2012 .Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pat- terns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis, 60(1) : 90-101.
Ho PM,Bryson CL,Rumsfeld JS .2009 .Medication adherence: its importance in cardiovascular outcomes. Circulation, 119 : 3028-35.
Arenas MD,Malek T,Alvarez-Ude F,Gil MT,Moledous A,Reig-Ferrer A .2010 .Spanish [with English abstract]. Nefrologia, 30(5) : 522-530.
Isakova T,Nickolas TL,Denburg M .2017 .- tary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis, 70(6) : 737-751.
Schmid H,Hartmann B,Schiffl H B .2009 .Adherence to prescribed oral medica- tion in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res, 14(5) : 185-190.
Karamanidou C,Clatworthy J,Weinman J,Horne R. .2008 .A systematic review of the prevalence and determinants of nonadherence to phos- phate binding medication in patients with end-stage renal disease. BMC Nephrol, 9 : 2.
Covic A,Rastogi A .2013 .Hyperphosphatemia in patients with ESRD: assess- ing the current evidence linking outcomes with treatment adherence. BMC Nephrol, 14(1) : 153.
Ghimire S,Castelino RL,Lioufas NM,Peterson GM,Zaidi ST .2015 .Nonad- herence to medication therapy in haemodialysis patients: a systematic review. PLoS One, 10(12) : e0144119.
Kalantar-Zadeh K .2013 .Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence, 7 : 379-390.
Waheed AA,Pedraza F,Lenz O,Isakova T. .2013 .Phosphate control in end- stage renal disease: barriers and opportunities. Nephrol Dial Transplant, 28(12) : 2961-2968.
Mathes T,Jaschinski T,Pieper D. .2014 .Adherence influencing factors - a systematic review of systematic reviews. Archives of public health, 72(1) : 37.
Falah H. Hadi1 ,Al-Asraf .2021 .Adherence to Phosphate Binder Therapy in Patient with Chronic Kidney Disease a Cross-Sectional Study. , : Iraq1.
Fusco N,Sils B,Graff JS,Kistler K,Ruiz K .2023 .Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. Journal of Managed Care & Specialty Pharmacy, 29(1) : 4-16.
Ahjel S.W. .2020 .Antineoplastic Effect of New Synthesized Compounds of 2-Thiouracil Sulfonamide Derivatives against Ovarian and Breast Carcinoma Cells" In Vitro Study". Systematic Reviews in Pharmacy, 11(4) : .
Al-Huesini Abbas,L.M. Abbas .2019 .. DMF Ameliorating Cerebral Ischemia/Reperfusion Injury in Meal Rats. Systematic Reviews in Pharmacy, 10(1) : .
0

Citations

0

Downloads

44

Views